Key result
Elevated high-sensitivity cardiac troponin levels were significantly associated with increased in-hospital mortality in patients with COVID-19 (pooled OR 22.7; 95% CI 13.6-38.1; P<.001).
Why the study?
Given the difficulty identifying COVID-19 patients at risk for severe disease early and the lack of a definitive risk stratification marker, this study clarified the association between hs-cTn-assessed myocardial injury and in-hospital mortality.
Does elevated hs-cTn predict in-hospital mortality in patients with COVID-19?
Population
1231 patients with laboratory-confirmed COVID-19 across 6 observational studies
Comparison
Elevated hs-cTn levels vs normal hs-cTn levels
Design
Systematic review and meta-analysis
Authors
Loading...
Supports hs-cTn for COVID-19 risk stratification; extends observational evidence but leaves causal role and practice change open.
Meta-Analysis (n=1,231)
Yes
Does elevated hs-cTn predict in-hospital mortality in patients with COVID-19?
Odds Ratio: 22.7 (95% CI 13.6–38.1)
p-value: p=<.001
Elevated hs-cTn levels are strongly associated with increased in-hospital mortality in COVID-19 patients, highlighting its potential as an early marker for risk stratification.
Aikawa et al. (2020) conducted a meta-analysis in COVID-19 (n=1,231). Elevated high-sensitivity cardiac troponin (hs-cTn) levels vs. Non-elevated hs-cTn levels was evaluated on In-hospital mortality (OR 22.7, 95% CI 13.6-38.1, p=<.001). Elevated high-sensitivity cardiac troponin levels were significantly associated with increased in-hospital mortality in patients with COVID-19 (pooled OR 22.7; 95% CI 13.6-38.1; P<.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: